77 completed, 4 recruiting, 2 active not recruiting, 1 terminated. 85 Phase 1, 18 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 85 | Completed 77, Recruiting 4, Active not recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 18 | Completed 16, Recruiting 1, Terminated 1 |
Follow Animal Diseases: new trials by email Literature Review of Animal Diseases trials Research Report on Animal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer HTR2 T Cells - Breast Cancer, Tumor, Breast | Phase 1 | Recruiting | Baylor College of Medicine | 27 | 2026-08-03 | 2026-09-24 |
| A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health rVSV∆G-MARV-GP, Placebo - Marburg Virus Disease | Phase 1 | Active not recruiting | International AIDS Vaccine Initiative | 112 | 2026-03-27 | 2026-10-30 |
| Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) 7.5 mcg, Monovalent influenza vaccine type A (H5N8) 15 mcg, Placebo - Avian Influenza A Virus | Phase 1 / Phase 2 | Recruiting | Butantan Institute | 700 | 2025-09-10 | 2026-04-02 |
| Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses. BSY001 for Injection (37.5mg), BSY001 for Injection (75 mg), BSY001 for Injection (150 mg) - Smallpox, Cowpox | Phase 1 | Recruiting | China National Biotec Group Company Limited | 76 | 2025-08-28 | 2026-01-29 |
| A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults H5 AC-Anhui RNA Vaccine, H5 Astrakhan RNA Vaccine, Sodium Chloride, 0.9% - Avian Influenza | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 80 | 2025-06-12 | 2026-06-12 |
| Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011 IDB-011 dose level 1, IDB-011 dose level 2, IDB-011 dose level 3 - Rift Valley Fever | Phase 1 | Active not recruiting | IDBiologics, Inc. | 40 | 2025-04-02 | 2026-03-25 |
| A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine MVA strain monkeypox attenuated live vaccine (low dose), MVA strain monkeypox attenuated live vaccine (high dose), Placebo - Monkeypox | Phase 1 | Recruiting | Shanghai Institute Of Biological Products | 120 | 2025-01-22 | 2025-10-03 |
| A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults Flu Pandemic mRNA_Dose level 1, Flu Pandemic mRNA_Dose level 2, Flu Pandemic mRNA_ Dose level 3. - Influenza, Human | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 991 | 2024-04-18 | 2026-02-05 |
| Study to Evaluate the Recombinant VSV (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects PHV01, Placebo - Marburg Virus Disease | Phase 1 | Completed | Public Health Vaccines LLC | 36 | 2024-02-05 | 2025-09-05 |
| A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines BNT166a - Monkeypox | Phase 1 / Phase 2 | Completed | BioNTech SE | 96 | 2023-09-21 | 2026-09-15 |
| A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age mRNA-1769, Placebo - Smallpox, Mpox | Phase 1 / Phase 2 | Completed | ModernaTX, Inc. | 351 | 2023-08-15 | 2025-07-16 |
| A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults ChAdOx1 RVF, Saline - RVF, Rift Valley Fever | Phase 1 | Completed | University of Oxford | 30 | 2022-05-31 | 2023-02-06 |
| Study of Efficacy and Safety of ABO809 in Healthy Participants Cryptosporidium parvum oocysts (ABO809) - Cryptosporidium Infection, Cryptosporidiosis | Phase 1 | Completed | Novartis Pharmaceuticals | 30 | 2022-04-07 | 2024-10-02 |
| A Phase 1 Study to Evaluate Safety & Immunogenicity of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects PHV02, Placebo - Nipah Virus Infection | Phase 1 | Completed | Public Health Vaccines LLC | 60 | 2022-01-10 | 2024-10-24 |
| Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults cAd3-Marburg, cAd3-EBO-S - Ebola Virus Disease, Marburg Virus Disease | Phase 1 | Completed | Albert B. Sabin Vaccine Institute | 32 | 2021-01-06 | 2022-08-03 |
| Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 once orally, NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 once orally. (Total 600 mg NIOCH-14 per day), NIOCH-14, 200 mg capsule: 6 capsules (200 mg each) of NIOCH-14 per day orally. (Total 1200 mg NIOCH-14 per day) - Smallpox, Monkeypox | Phase 1 | Completed | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | 90 | 2020-09-04 | 2023-08-04 |
| Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years VAC∆6 vaccine - оnce at a dose of 10⁶ PFU, VAC∆6 vaccine - once at a dose of 10⁷ PFU, VAC∆6 vaccine - twice at a dose of 10⁶ PFU - Smallpox, Monkeypox | Phase 1 | Completed | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | 60 | 2019-05-18 | 2023-03-09 |
| A Bridging Study of the SYN023 on Healthy Adult Subjects recombinant anti-rabies human monoclonal antibody injection (SYN023), Rabies Vaccine - Communicable Disease Transmission, Zoonotic Disease | Phase 1 / Phase 2 | Completed | Synermore Biologics (Suzhou) Co., Ltd. | 33 | 2019-02-26 | 2021-09-29 |
| A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430 galidesivir, placebo - Marburg Virus Disease | Phase 1 | Completed | BioCryst Pharmaceuticals | 32 | 2018-12-10 | 2021-07-23 |
| cAd3-Marburg Vaccine in Healthy Adults cAd3-Marburg vaccine - Marburg Virus Disease | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 40 | 2018-10-09 | 2022-08-11 |
Showing 20 of 85. Sign in to see all of them.
Influenza in Birds (53) · Influenza, Human (35) · Marburg Virus Disease (10) · Mpox, Monkeypox (8) · Virus Diseases (8) · Cryptosporidiosis (6) · Smallpox (6) · HIV Infections (5) · Acquired Immunodeficiency Syndrome (4) · Hemorrhagic Fever, Ebola (4) · Cowpox (3) · Diarrhea (3) · AIDS-Related Opportunistic Infections (2) · Furunculosis (2) · Rift Valley Fever (2)
Infections (84) · Virus Diseases (72) · RNA Virus Infections (71) · Bird Diseases (54) · Orthomyxoviridae Infections (52) · Respiratory Tract Infections (35) · Respiratory Tract Diseases (34) · Primate Diseases (18) · Hemorrhagic Fevers, Viral (11) · Mononegavirales Infections (11) · DNA Virus Infections (10) · Filoviridae Infections (10) · Monkey Diseases (10) · Digestive System Diseases (9)
Influenza Vaccines (5) · Sodium Chloride (3) · AS03 adjuvant (2) · Aluminum Hydroxide (2) · Vaccines (2) · AVI-7288 (1) · Adjuvants, Pharmaceutic (1) · Ebola Vaccines (1) · Hydroxychloroquine (1) · Imiquimod (1) · Injections (1) · Interleukin-12 (1) · MF59 oil emulsion (1) · NIOCH-14 (1) · Oseltamivir (1)
National Institute of Allergy and Infectious Diseases (NIAID) (37) · Alachua Government Services, Inc. (2) · Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" (2) · Inovio Pharmaceuticals (2) · Mahidol University (2) · Public Health Vaccines LLC (2) · Sarepta Therapeutics, Inc. (2) · Vaxart (2) · Vical (2) · AVIR Green Hills Biotechnology AG (1) · Albert B. Sabin Vaccine Institute (1) · Altimmune, Inc. (1) · Baylor College of Medicine (1) · BioCryst Pharmaceuticals (1) · BioNTech SE (1)
United States (61) · Russia (4) · Australia (3) · China (3) · Thailand (3) · Finland (2) · South Korea (2) · Uganda (2) · United Kingdom (2) · Austria (1) · Belgium (1) · Brazil (1) · Singapore (1) · South Africa (1) · Spain (1)
Ruth A. Karron, MD (4) · Don Guterwill, BS, MT (2) · Vladimir I. Kuzubov, PhD (2) · Alison Heald, MD (1) · Apinya B Vutikullird, MD (1) · Arthur White (1) · Carlos Fierro, MD (1) · D. Nigel Thomas, Ph.D. (1) · Daniel Dickerson, MD, PhD (1) · David Hoover, MD (1) · David Liebowitz, MD, PhD (1) · Dimitar Sajkov, MD, PhD (1) · Elena M Gonzalez Brant, MD (1)
PMID 19540952, PMID 21975270, PMID 1538192, PMID 15577929, PMID 16375711, PMID 18260764, PMID 18576945, PMID 18808338, PMID 19210163, PMID 19464558, PMID 22542645, PMID 23357198, PMID 23369412, PMID 23633404, PMID 23633407, PMID 24041789, PMID 24224560, PMID 24533064, PMID 25225676, PMID 25426834, PMID 25540891, PMID 25662592, PMID 25734159, PMID 26200980, PMID 26432909, PMID 28099485, PMID 29261658, PMID 31155415, PMID 31255574, PMID 33091433, PMID 33852718, PMID 35115707, PMID 35182042, PMID 36263798, PMID 36709074, PMID 38181048, PMID 38366591, PMID 39715748, PMID 41237791, PMID 42201116, PMID 42235570, PMID 8237108
272201300017C-18-0-1 (1), R01AI041735 (1)